Literature DB >> 28163027

Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia.

J Douglas Thornton, Elizabeth Lyvers, Virginia Ginger G Scott, Nilanjana Dwibedi.   

Abstract

OBJECTIVES: The objective of this study is to assess West Virginia pharmacists' stocking and dispensing practices of opioid-related medications and to identify the educational needs relating to providing naloxone in community pharmacies.
DESIGN: A cross-sectional, anonymous, 49-item survey was created and validated to assess the educational needs of West Virginia community pharmacists.
SETTING: West Virginia. PARTICIPANTS: The data collection instrument was administered to 266 pharmacists currently licensed in West Virginia at 6 continuing pharmacy education events throughout the state from March 1 to June 15, 2016. OUTCOME MEASURES: Pharmacists' educational needs were determined using the Extended Parallel Process Model, which has 4 main constructs: perceived severity, perceived susceptibility, response efficacy, and self-efficacy. Pharmacists' stocking and dispensing of opioids and related medications were also assessed.
RESULTS: Pharmacists completed 157 surveys. They were mostly male (56.1%), full-time employees (67.5%), worked mostly in community pharmacies (69.4%), and had a mean age of 50.19 years (SD = 13.62). The newly adapted opioid perceived efficacy and perceived severity of opioid adverse events scales were tested for reliability and validity. Only 20.4% of the community pharmacists surveyed felt comfortable selling naloxone without a prescription. As for the other opioid-related medications, only 53.3% stocked buprenorphine and 74.8% stocked buprenorphine/naloxone.
CONCLUSIONS: As the most accessible health care providers, community pharmacists are acutely aware of how the opioid epidemic affects their communities. Some pharmacists in West Virginia are hesitant to stock and dispense opioids and opioid-dependence medications. Although this may decrease the flow of potentially abused drugs into the community, it may also restrict access to necessary therapy for patients with opioid use disorder. Furthermore, pharmacists in West Virginia are not yet comfortable stocking and dispensing naloxone. Tailored educational materials can help in controlling the pharmacists' fear and reinforce the benefits of over-the-counter naloxone use.
Copyright © 2017 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28163027      PMCID: PMC5352525          DOI: 10.1016/j.japh.2016.12.070

Source DB:  PubMed          Journal:  J Am Pharm Assoc (2003)        ISSN: 1086-5802


  13 in total

1.  Concern about the Expanding Prescription Drug Epidemic: A Survey of Licensed Prescribers and Dispensers.

Authors:  R Eric Wright; Nia Reed; Neal Carnes; Harold E Kooreman
Journal:  Pain Physician       Date:  2016-01       Impact factor: 4.965

Review 2.  Current State of Opioid Therapy and Abuse.

Authors:  Laxmaiah Manchikanti; Adam M Kaye; Alan D Kaye
Journal:  Curr Pain Headache Rep       Date:  2016-05

3.  Increases in Drug and Opioid Overdose Deaths--United States, 2000-2014.

Authors:  Rose A Rudd; Noah Aleshire; Jon E Zibbell; R Matthew Gladden
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-01-01       Impact factor: 17.586

4.  Clinicians' attitudes and beliefs about opioids survey (CAOS): instrument development and results of a national physician survey.

Authors:  Hilary D Wilson; Elizabeth J Dansie; Myoung S Kim; Bruce L Moskovitz; Wing Chow; Dennis C Turk
Journal:  J Pain       Date:  2013-03-26       Impact factor: 5.820

5.  Characteristics of an overdose prevention, response, and naloxone distribution program in Pittsburgh and Allegheny County, Pennsylvania.

Authors:  Alex S Bennett; Alice Bell; Laura Tomedi; Eric G Hulsey; Alex H Kral
Journal:  J Urban Health       Date:  2011-12       Impact factor: 3.671

6.  Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.

Authors:  Abby M Bailey; Daniel P Wermeling
Journal:  Ann Pharmacother       Date:  2014-02-12       Impact factor: 3.154

7.  Nonrandomized Intervention Study of Naloxone Coprescription for Primary Care Patients Receiving Long-Term Opioid Therapy for Pain.

Authors:  Phillip O Coffin; Emily Behar; Christopher Rowe; Glenn-Milo Santos; Diana Coffa; Matthew Bald; Eric Vittinghoff
Journal:  Ann Intern Med       Date:  2016-06-28       Impact factor: 25.391

Review 8.  Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.

Authors:  Jennifer S Orman; Gillian M Keating
Journal:  Drugs       Date:  2009       Impact factor: 9.546

9.  Orienting patients to greater opioid safety: models of community pharmacy-based naloxone.

Authors:  Traci C Green; Emily F Dauria; Jeffrey Bratberg; Corey S Davis; Alexander Y Walley
Journal:  Harm Reduct J       Date:  2015-08-06

Review 10.  Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures.

Authors:  Emmanuelle Anthoine; Leïla Moret; Antoine Regnault; Véronique Sébille; Jean-Benoit Hardouin
Journal:  Health Qual Life Outcomes       Date:  2014-12-09       Impact factor: 3.186

View more
  16 in total

1.  Reviewing state-mandated training requirements for naloxone-dispensing pharmacists.

Authors:  Andrew W Roberts; Delesha M Carpenter; Austin Smith; Kevin A Look
Journal:  Res Social Adm Pharm       Date:  2018-04-05

2.  Evaluating Pharmacy Student Consultations with Standardized Patients on Opioid Medication Use and Opioid-Specific Risks.

Authors:  Tanvee Thakur; Meredith Frey; Betty Chewning
Journal:  Am J Pharm Educ       Date:  2019-12       Impact factor: 2.047

3.  Opioid-Related Education Provided by Continuing Education Divisions at US Pharmacy Schools.

Authors:  Mandy L Renfro; Leticia R Moczygemba; Jennifer Baumgartner; Glen Baumgart; Lucas G Hill
Journal:  Am J Pharm Educ       Date:  2020-10       Impact factor: 2.047

4.  Take-home naloxone possession among people who inject drugs in rural West Virginia.

Authors:  Sean T Allen; Rebecca Hamilton White; Allison O'Rourke; Suzanne M Grieb; Michael E Kilkenny; Susan G Sherman
Journal:  Drug Alcohol Depend       Date:  2019-09-21       Impact factor: 4.492

5.  Legal requirements and recommendations to prescribe naloxone.

Authors:  Rebecca L Haffajee; Samantha Cherney; Rosanna Smart
Journal:  Drug Alcohol Depend       Date:  2020-02-06       Impact factor: 4.492

Review 6.  Pharmacists' attitudes toward dispensing naloxone and medications for opioid use disorder: A scoping review of the literature.

Authors:  Andrew Muzyk; Zachary P W Smothers; Kathryn Collins; Mark MacEachern; Li-Tzy Wu
Journal:  Subst Abus       Date:  2019-08-16       Impact factor: 3.716

7.  Limited access to pharmacy-based naloxone in West Virginia: Results from a statewide purchase trial.

Authors:  Robin A Pollini; Jenny E Ozga; Rebecca Joyce; Ziming Xuan; Alexander Y Walley
Journal:  Drug Alcohol Depend       Date:  2021-12-31       Impact factor: 4.492

8.  Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: A case study of the rural risk environment in Appalachian Kentucky.

Authors:  Hannah Lf Cooper; David H Cloud; Patricia R Freeman; Monica Fadanelli; Travis Green; Connor Van Meter; Stephanie Beane; Umedjon Ibragimov; April M Young
Journal:  Int J Drug Policy       Date:  2020-03-26

9.  Community Pharmacist Utilization of Legislation That Allows Impact on the Opioid Crisis in the State of Minnesota: A Mixed-Methods Approach.

Authors:  Laura Palombi; Amanda N Hawthorne; Scott Lunos; Kelsey Melgaard; Ashley Dahly; Heather Blue
Journal:  J Pharm Pract       Date:  2019-04-14

10.  Acceptability of Naloxone Dispensing Among Pharmacists.

Authors:  Vivian Do; Emily Behar; Caitlin Turner; Michelle Geier; Phillip Coffin
Journal:  J Pharm Pract       Date:  2018-09-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.